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Objective Lower maternal vitamin D status in
pregnancy may be associated with increased offspring
cardiovascular risk in later life, but evidence for this is
scant. We examined associations of maternal total
25-hydroxyvitamin D (25(OH)D) in pregnancy with
offspring cardiovascular risk factors assessed in
childhood and adolescence.
Design A longitudinal, prospective study.
Setting The study was based on data from mother–
offspring pairs in the Avon Longitudinal Study of Parents
and Children (ALSPAC), a UK prospective population-
based birth cohort (N=4109).
Outcome measures Offspring cardiovascular risk
factors were measured in childhood (mean age
9.9 years) and in adolescence (mean age 15.4 years):
blood pressure, lipids, apolipoproteins (at 9.9 years only),
glucose and insulin (at 15.4 years only), C reactive
protein (CRP), and interleukin 6 (at 9.9 years only) were
measured.
Results After adjustments for potential confounders
(maternal age, education, body mass index (BMI),
smoking, physical activity, parity, socioeconomic position,
ethnicity, and offspring gestational age at 25(OH)D
sampling; gender, age, and BMI at outcome
assessment), maternal 25(OH)D was inversely associated
with systolic blood pressure (−0.48 mm Hg difference
per 50 nmol/L increase in 25(OH)D; 95% CI −0.95 to
−0.01), Apo-B (−0.01 mg/dL difference; 95% CI −0.02
to −0.001), and CRP (−6.1% difference; 95% CI
−11.5% to −0.3%) at age 9.9 years. These associations
were not present for risk factors measured at 15.4 years,
with the exception of a weak inverse association with
CRP (−5.5% difference; 95% CI −11.4% to 0.8%).
There was no strong evidence of associations with
offspring triglycerides, glucose or insulin.
Conclusions Our ﬁndings suggest that fetal exposure
to 25(OH)D is unlikely to inﬂuence cardiovascular risk
factors of individuals later in life.
INTRODUCTION
Low vitamin D status, assessed by circulating total
25-hydroxyvitamin D (25(OH)D), is common in
pregnancy.1 2 Maternal 25(OH)D diffuses freely
across the placenta, and fetal exposure to vitamin D
depends solely on concentrations in the mother.3
There is increasing evidence that vitamin D status in
pregnancy may inﬂuence normal fetal growth and
development, and inﬂuence offspring health out-
comes in later life. Recent observational studies have
reported associations of low maternal 25(OH)D
concentrations or dietary vitamin D intake with
lower bone mineral accrual,4 5 and increased risk of
type 1 diabetes6 and wheezing7 in offspring. It has
also been suggested that lower concentrations of
maternal 25(OH)D in pregnancy might be related to
increased risk of insulin resistance (measured by the
homeostasis model of assessment-insulin resistance;
HOMA-IR), and hence cardiovascular disease, in
offspring in later life.8
There are several plausible pathways by which
maternal 25(OH)D in pregnancy may relate to future
cardiovascular health of offspring. First, some,9–11
though not all,12 13 studies have shown an association
of lower 25(OH)D concentration in pregnancy with
maternal risk of pre-eclampsia and with low birth
weight/risk of a small for gestational age birth in their
infants, and these have been associated with future
cardiovascular risk in offspring.14–16 Secondly, a
number of studies have reported associations of
lower circulating 25(OH)D with adverse cardiovascu-
lar risk factors in children, adolescents, and
adults.17 18 It is therefore possible that maternal 25
(OH)D in pregnancy will be associated with offspring
cardiovascular risk factors because maternal and off-
spring 25(OH)D are correlated due to shared envir-
onmental and genetic determinants of 25(OH)D
(ie, maternal 25(OH)D in pregnancy will relate to
offspring outcomes at least in part because it reﬂects
the child’s own concentrations). Thirdly, it is possible
that variation in exposure to intrauterine concentra-
tions of 25(OH)D programmes fetal development
and inﬂuences arterial structure and metabolic pro-
cesses that affect future cardiovascular health.
However, only two small studies have examined asso-
ciations of maternal 25(OH)D concentrations during
pregnancy and cardiovascular disease risk factors of
offspring to date.8 19 The small sample sizes of both
of these studies (with 178 and 539 maternal–
offspring pairs) could have limited their ability to
detect associations.
Our aim was to examine associations of maternal
25(OH)D concentrations measured in pregnancy
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with a range of offspring cardiovascular risk factors (blood pres-
sure, lipids, apolipoproteins (Apo-A1, Apo-B), fasting glucose
and insulin, C reactive protein (CRP), and interleukin 6 (IL6))
measured during childhood (mean age 9.9 years) and again in
adolescence (mean age 15.4 years).
METHODS
Participants
The Avon Longitudinal Study of Parents and Children (ALSPAC)
is a prospective birth cohort that recruited pregnant women
(N=14 541) living within the former county of Avon, South
West England. Women with an expected delivery date between
1 April 1991 and 31 December 1992 were eligible to be
included. Study details have been published,20 21 and are found
online at http://www.bristol.ac.uk/alspac/. A total of 13 988 live
born children who survived past age 1 year have been followed
up alongside their mothers with questionnaires during early
childhood, and at regular assessments from age 7. Ethical
approval was granted by the ALSPAC Law and Ethics
Committee and the local research ethics committee. Written
informed consent/assent was obtained from both parents/guar-
dians and the children. For this study, we used measures of
25(OH)D concentrations from blood samples collected from
mothers during pregnancy as part of their routine follow-up,
and offspring cardiovascular risk factors measured when the off-
spring attended the year 9.9 and 15.4 year follow-up assess-
ments. Our eligible sample consists of 4109 maternal–offspring
pairs with a maternal 25(OH)D measure from pregnancy and
offspring cardiovascular risk factors measured at mean age 9.9
or 15.4 years (see ﬁgure 1).
Measures
Details of 25(OH)D assaying, and measurements of outcomes
and co-variables, are included in the online supplementary
material.
Statistical analysis
A large proportion of our sample (N=3169; 77.1%) had mater-
nal 25(OH)D2 concentrations at or below the assay detection
limit (1.25 nmol/L). These were assigned a value of 0 nmol/L.
A measure of total 25(OH)D was then calculated from the sum
of 25(OH)D2 and 25(OH)D3 and all associations are of mater-
nal total 25(OH)D with offspring outcomes. 25(OH)D was
adjusted for season of sampling, as previously described.18
Brieﬂy, 25(OH)D was modelled against the date of blood sam-
pling using linear regression with trigonometric sine and cosine
functions, and residuals of regression models were used as
season-adjusted 25(OH)D in main analyses.
To test the strength of linear associations between the 25
(OH)D measures (unadjusted and season-adjusted maternal 25
(OH)D, and unadjusted and season-adjusted offspring 25
(OH)D), we calculated Pearson correlation coefﬁcients for pairs
of measures.
Multivariable linear regression models were used to examine
associations of maternal 25(OH)D with cardiovascular risk
factors, and to adjust for potential confounding and mediating
factors. Regression coefﬁcients and 95% CI were formatted to
show mean differences in outcomes per 50 nmol/L increase in
25(OH)D. Coefﬁcients for log-transformed outcomes (triglycer-
ides, insulin, CRP, and IL6) were expressed in terms of relative
percent change per 50 nmol/L increase in 25(OH)D, by
reformatting ratios of geometric means and 95% CIs.
We conducted several multivariable linear regression models
for each exposure-outcome association. In model 1, associations
were adjusted for maternal age at delivery, offspring gender, ges-
tational age at 25(OH)D sampling, age at the year 9.9 or 15.4
assessments, parity, maternal education, household socio-
economic position, ethnicity, maternal pre-pregnancy body mass
index (BMI), smoking and physical activity in pregnancy, and
offspring BMI at the year 9.9 or 15.4 assessment. We included
adjustment for offspring BMI because maternal 25(OH)D is
inversely associated with maternal BMI, a mother’s BMI may
relate to her child’s BMI, and offspring BMI is associated with
their cardiovascular risk factors. As such, offspring BMI could
lie on the confounding pathway. In model 2, we additionally
adjusted for potential mediation of associations by offspring
25(OH)D measured in childhood. Model 3 included adjust-
ments for confounders as in model 2, and additional adjust-
ments for potential mediation by gestational hypertension,
pre-eclampsia, gestational diabetes mellitus or glycosuria during
pregnancy, and birth weight. Possible non-linearity of associa-
tions between exposures and outcomes was tested by examining
fractional polynomial statistics and interpreting graphical
plots.22
In addition to examining linear associations, we also con-
ducted multivariable regression analyses examining mean differ-
ences of cardiovascular risk factors in offspring with maternal
25(OH)D <50 nmol/L and in offspring with maternal 25
(OH)D between 50–75 nmol/L, compared to risk factors in off-
spring with maternal 25(OH)D > 75 nmol/L.2
Missing data
There were proportions of our eligible sample who had missing
data on one or more variable used to examine associations with
cardiovascular risk factors at 9.9 years (N=2010; 48.9%) and
15.4 years (N=2807; 68.3%). To address this, we used multi-
variate multiple imputation to impute missing information on
outcomes and covariables for otherwise eligible maternal–off-
spring pairs with valid maternal 25(OH)D measures from preg-
nancy and who had attended the year 9.9 or 15.4 assessments.
This approach involves switching regression, using the multivari-
ate imputation by chained equations function in Stata.23 Twenty
cycles of regression switching were used, and estimates of
results were averaged across the 20 imputed datasets according
to Rubin’s rules.23 Main analyses were conducted using these
datasets.
Additional analyses
We repeated main analyses using maternal 25(OH)D unadjusted
for season of sampling as an exposure. We also repeated main
analyses excluding participants whose CRP values suggested
acute inﬂammation (CRP > 6 mg/L).
We tested associations for interactions between maternal
25(OH)D concentrations and trimester of sampling, and exam-
ined results after stratifying by trimester.
We also conducted analyses in the subsamples of participants
with complete information on maternal 25(OH)D, co-variables
and offspring cardiovascular risk factors at mean age 9.9 years
(N=2099) and 15.4 years (N=1302).
Given that non-high density lipoprotein cholesterol
(non-HDL-C: total cholesterol minus HDL-C) has been impli-
cated as being more strongly associated with cardiovascular
events than separate lipid components alone,24 we also repeated
analyses including non-HDL-C as an outcome. Since a previous
study has reported an inverse association of maternal 25(OH)D
in pregnancy with offspring insulin resistance as measured by
HOMA-IR,8 we also repeated analyses with this measure as an
outcome, calculated using the standard formula.25
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RESULTS
Characteristics of ALSPAC mothers and offspring in the eligible
sample, along with characteristics of those who were excluded
because of missing data, are shown in online supplemental
tables S1 and S2.
Table 1 shows characteristics of ALSPAC mothers and offspring
according to categories of maternal 25(OH)D in pregnancy.
Maternal age at 25(OH)D sampling in pregnancy, socioeconomic
position, maternal education, physical activity, percentage who
had never smoked during pregnancy, gestational age at 25(OH)D
sampling, birth weight, and offspring 25(OH)D all increased lin-
early from lower to higher maternal 25(OH)D categories. Parity,
percentage of non-white European ethnicity, and percentage who
smoked throughout pregnancy all decreased across categories of
maternal 25(OH)D. Of risk factors measured at mean age
9.9 years, HDL-C and Apo-A1 increased across low to high cat-
egories of maternal 25(OH)D, while diastolic blood pressure
(DBP), low density lipoprotein cholesterol (LDL-C) and Apo-B
decreased across the categories. Similar trends were observed for
LDL-C, HDL-C, and CRP measured at mean age 15.4 years. No
trends with other risk factors were observed.
Online supplemental table S3 shows correlations of unadjusted
and season-adjusted maternal 25(OH)D, and also offspring
unadjusted and season-adjusted 25(OH)D sampled at mean age
9.8 years. There were weak positive correlations of unadjusted
and season-adjusted maternal 25(OH)D with unadjusted and
season-adjusted offspring 25(OH)D (all Pearson’s r=0.11 to
0.15; all p<0.001).
Table 2 shows multivariable associations of maternal
25(OH)D with offspring cardiovascular risk factors. In model 1,
there were inverse associations of maternal 25(OH)D with sys-
tolic blood pressure (SBP), Apo-B and CRP, and weak inverse
associations with DBP and IL6, at mean age 9.9 years. At mean
age 15.4 years there were no associations with SBP or DBP, but a
weak inverse association with CRP was present. Further adjust-
ments for offspring 25(OH)D (model 2) and other potential
mediators (model 3) did not substantially change results
observed in model 1, although the association of 25(OH)D with
CRP at 9.9 years attenuated slightly in model 2. Figure 2 shows
the confounder-adjusted associations with risk factors that were
measured at both ages, with all results on a scale of percentage
difference per 50 nmol/L increase in 25(OH)D. It can be seen
that the directions and magnitudes of associations with CRP are
similar at both age points.
Online supplemental table S4 shows mean differences in cardio-
vascular risk factors in offspring whose mothers had 25(OH)D
from 50–75 nmol/L or 25(OH)D<50 nmol/L in pregnancy, com-
pared to those whose mothers had 25(OH)D>75 nmol/L. On
average, Apo-B at 9.9 years was higher in offspring with maternal
25(OH)D concentrations <50 nmol/L or 50–75 nmol/L compared
Figure 1 Flow chart of study participants. 25(OH)D, 25-hydroxyvitamin D; ALSPAC, Avon Longitudinal Study of Parents and Children.
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Table 1 Characteristics of ALSPAC mothers and offspring by categories of maternal 25(OH)D concentration pregnancy (% or mean and
95% CI; the column marked ‘N’ denotes the number of participants in the analysis sample with available data for each variable)
N 25(OH)D<25 nmol/L
25(OH)
D=25–49.9 nmol/L 25(OH)D=50–75 nmol/L 25(OH)D>75 nmol/L p Value
Maternal characteristics
Maternal age at delivery 4031 27.5 (26.7 to 28.2) 28.6 (28.3 to 28.8) 28.8 (28.6 to 29.1) 29.4 (29.2 to 29.6) <0.001
% Parity 4109
0 55.8 47.0 45.9 42.1 0.001
1 32.7 34.4 34.2 38.4 0.02
2 9.5 13.3 15.0 14.4 0.15
3 2.0 3.2 4.0 4.5 0.05
4 or 5 0.0 2.0 0.9 0.6 0.02
% Non-white European ethnicity 4109 8.5 2.5 1.2 0.9 <0.001
% Socioeconomic position 4109
I/II 51.9 56.3 59.6 61.7 <0.001
III (non-manual) 28.2 26.2 25.7 24.0 0.35
III (manual) 14.8 12.8 10.6 10.7 0.10
IV/V 5.2 4.8 4.2 3.7 0.22
Maternal education (% attended university) 3868 12.1 14.9 15.1 16.7 0.09
Pre-pregnancy BMI 3620 22.7 (22.1 to 23.3) 22.9 (22.7 to 23.1) 22.9 (22.7 to 23.1) 22.7 (22.5 to 22.9) 0.20
Maternal smoking (%) 4109
Never 72.5 75.0 80.7 83.4 <0.001
Before or during first trimester 4.0 6.7 5.7 5.4 0.44
Throughout pregnancy 23.5 18.3 13.6 11.3 <0.001
Maternal physical activity in pregnancy (MET)* 3268 9.9 (8.2 to 12.0) 11.3 (10.5 to 12.1) 12.0 (11.2 to 12.8) 12.6 (11.9 to 13.4) 0.003
% Gestational hypertension 3947 15.5 14.4 15.3 13.0 0.23
% Pre-eclampsia 4013 2.6 1.8 1.4 1.6 0.42
% Gestational diabetes 3951 0.0 0.7 0.8 0.5 0.98
% Glycosuria in pregnancy 4109 2.5 3.2 2.8 2.4 0.31
Offspring characteristics
% male 4109 54.4 49.5 51.9 52.2 0.39
Gestational age at 25(OH)D sampling (weeks) 4109 24.0 (22.3 to 25.7) 23.4 (22.8 to 24.0) 23.7 (23.1 to 24.3) 25.7 (25.1 to 26.2) <0.001
Birth weight (kg) 3982 3.3 (3.2 to 3.4) 3.4 (3.4 to 3.5) 3.4 (3.4 to 3.5) 3.5 (3.5 to 3.5) <0.001
Age at year 9.9 assessment (years) 3566 9.94 (9.89 to 10.00) 9.87 (9.85 to 9.89) 9.84 (9.82 to 9.86) 9.86 (9.85 to 9.88) 0.16
Age at year 15.4 assessment (years) 2521 15.51 (15.44 to 15.57) 15.45 (15.42 to 15.47) 15.44 (15.42 to 15.46) 15.44 (15.42 to 15.46) 0.21
BMI at year 9.9 assessment (kg/m2) 3525 17.6 (17.1 to 18.0) 17.7 (17.5 to 17.8) 17.6 (17.4 to 17.8) 17.7 (17.5 to 17.8) 0.87
BMI at year 15.4 assessment (kg/m2) 2497 21.4 (20.7 to 22.1) 21.3 (21.1 to 21.6) 21.3 (21.1 to 21.6) 21.2 (20.9 to 21.4) 0.27
Childhood 25(OH)D (nmol/L) 4099 22.9 (21.4 to 24.3) 24.4 (23.8 to 24.9) 25.3 (24.8 to 25.9) 26.6 (26.1 to 27.0) <0.001
Year 9.9 risk factors
SBP (mm Hg) 3525 102.9 (101.4 to 104.5) 102.9 (102.3 to 103.5) 102.5 (101.9 to 103.0) 102.3 (101.8 to 102.8) 0.10
DBP (mm Hg) 3527 57.6 (56.5 to 58.7) 57.7 (57.3 to 58.1) 57.3 (56.9 to 57.6) 57.2 (56.8 to 57.5) 0.05
Triglycerides (mmol/L)† 2770 0.99 (0.91 to 1.08) 1.05 (1.02 to 1.08) 1.03 (1.00 to 1.06) 1.03 (1.00 to 1.06) 0.80
LDL-C (mmol/L) 2770 2.39 (2.28 to 2.51) 2.37 (2.32 to 2.41) 2.32 (2.28 to 2.36) 2.31 (2.28 to 2.35) 0.05
HDL-C (mmol/L) 2770 1.38 (1.32 to 1.44) 1.38 (1.36 to 1.40) 1.41 (1.39 to 1.43) 1.41 (1.39 to 1.43) 0.02
Apo-A1 (mg/dL) 2770 1.33 (1.29 to 1.37) 1.35 (1.34 to 1.37) 1.37 (1.35 to 1.38) 1.37 (1.35 to 1.38) 0.04
Apo-B (mg/dL) 2770 0.61 (0.58 to 0.63) 0.60 (0.59 to 0.61) 0.59 (0.58 to 0.59) 0.58 (0.57 to 0.59) 0.002
CRP (mg/L)† 2388 0.26 (0.21 to 0.33) 0.29 (0.27 to 0.31) 0.26 (0.24 to 0.28) 0.26 (0.24 to 0.28) 0.10
IL6 (pg/mL)† 2760 0.86 (0.73 to 1.01) 0.88 (0.83 to 0.94) 0.83 (0.78 to 0.88) 0.82 (0.78 to 0.87) 0.12
Year 15.4 risk factors
SBP (mm Hg) 2388 122.6 (120.3 to 125.0) 122.7 (121.8 to 123.5) 122.7 (122.0 to 123.5) 123.5 (122.7 to 124.2) 0.15
DBP (mm Hg) 2388 67.5 (65.7 to 69.4) 67.5 (66.8 to 68.1) 67.2 (66.6 to 67.8) 67.7 (67.2 to 68.3) 0.55
Triglycerides (mmol/L)† 1760 0.77 (0.71 to 0.85) 0.77 (0.75 to 0.80) 0.77 (0.75 to 0.79) 0.76 (0.74 to 0.78) 0.33
LDL-C (mmol/L) 1760 2.16 (2.02 to 2.29) 2.11 (2.06 to 2.16) 2.08 (2.03 to 2.12) 2.07 (2.02 to 2.11) 0.12
HDL-C (mmol/L) 1760 1.25 (1.17 to 1.32) 1.27 (1.24 to 1.30) 1.27 (1.25 to 1.30) 1.30 (1.27 to 1.32) 0.07
Glucose (mmol/L) 1760 5.22 (5.12 to 5.32) 5.17 (5.13 to 5.20) 5.21 (5.17 to 5.24) 5.21 (5.18 to 5.24) 0.15
Insulin (IU/L)† 1757 9.18 (8.13 to 10.35) 8.77 (8.40 to 9.17) 8.94 (8.58 to 9.31) 8.81 (8.49 to 9.14) 0.83
CRP (mg/L)† 1760 0.64 (0.49 to 0.84) 0.52 (0.47 to 0.57) 0.52 (0.48 to 0.57) 0.44 (0.41 to 0.48) 0.001
*MET, metabolic equivalent.
†Geometric means.
25(OH)D, Total 25-hydroxyvitamin D; ALSPAC, Avon Longitudinal Study of Parents and Children; Apo-A1, apolipoprotein-A1; Apo-B, apolipoprotein-B; BMI, body mass index; CRP, C
reactive protein; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; IL6, interleukin 6; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure.
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to those with maternal 25(OH)D>75 nmol/L. This difference was
small but followed a dose-response pattern. HDL-C was also
lower, and CRP higher, at 15.4 years in those in lower maternal 25
(OH)D categories compared to those with maternal 25(OH)
D>75 nmol/L. Further adjustments for potential mediators pro-
duced similar results to model 1 for all risk factor associations
(model 2 data shown in online supplemental table S5; model 3
data available on request).
There was no evidence that any association deviated from lin-
earity (all fractional polynomial p≥0.15). There was also limited
evidence of interactions between trimester of pregnancy in which
25(OH)D was sampled and associations of season-adjusted
maternal 25(OH)D with offspring cardiovascular risk factors.
The exception was the association with LDL-C at age 9.9 years
(p for interaction=0.02; all other p≥0.24). There was an inverse
association of LDL-C with maternal 25(OH)D sampled in trimes-
ter 1, but not with 25(OH)D sampled in trimesters 2 or 3.
In general, the directions and magnitudes of associations of
maternal 25(OH)D unadjusted for season of sampling with car-
diovascular risk factors were very similar to results of main ana-
lyses (see online supplemental table S6). The results of analyses
conducted on complete case subsamples are shown in online
supplemental table S7. Results were similar to those of analyses
conducted on imputed datasets; the main notable difference was
an absence of an inverse association of maternal 25(OH)D with
SBP measured at 9.9 years, and the presence of an inverse asso-
ciation with LDL-C at 15.4 years.
Removing participants with high CRP values (>6 mg/L) did
not appreciably change associations for inﬂammatory markers,
although the inverse association of maternal 25(OH)D with CRP
at 15.4 years strengthened. In the confounder-adjusted model,
there was a −6.2% difference in CRP per 50 nmol/L increase in
season-adjusted maternal 25(OH)D (95% CI −11.6 to −0.4).
Analyses using non-HDL-C and HOMA-IR as outcomes were
consistent with those using LDL-C and fasting insulin, respect-
ively (data available on request).
DISCUSSION
This study provides limited evidence to support the hypothesis
that intrauterine 25(OH)D exposure inﬂuences cardiovascular
risk factors measured in childhood and adolescence. We found
inverse associations between maternal 25(OH)D measured in
pregnancy and offspring CRP measured in childhood and ado-
lescence. We also found evidence for inverse associations of
maternal 25(OH)D with offspring SBP and Apo-B at 9.9 years,
although there was no association with SBP measured at
15.4 years (Apo-B measurements at 15.4 years were not avail-
able). There was no consistent evidence for associations with the
following cardiovascular risk factors measured at either assess-
ment: DBP, lipids, IL6, and fasting glucose and insulin (the latter
two risk factors measured only in adolescence).
Two small existing studies have examined maternal 25(OH)D
concentrations in pregnancy in relation to offspring cardiovascu-
lar risk factors in childhood.8 19 In the current study, there was
some evidence for an inverse association of maternal 25(OH)D
with offspring SBP in childhood, which contrasts with the two
previous studies of this nature. However, our results also suggest
that associations with blood pressure are not present after child-
hood. The lack of consistent associations with offspring blood
pressure at both of the age points counters the hypothesis that
exposure to maternal 25(OH)D in pregnancy helps to pro-
gramme lifelong blood pressure in offspring. Fasting insulin at
9.5 years was higher in Indian offspring of mothers with
25(OH)D<50 nmol/L in pregnancy than those whose mothers
had 25(OH)D over 50 nmol/L (N=578),8 but we found no
similar relation of maternal 25(OH)D to fasting insulin of off-
spring at 15.4 years. Although we cannot rule out potential
ethnic differences in associations, the ﬁndings of this study
suggest that the effects of in utero 25(OH)D on fetal pancreatic
development, β-cell function or mechanisms for glucose homeo-
stasis are limited, and maternal 25(OH)D in pregnancy is
unlikely to be a key aetiological risk factor for the future devel-
opment of type-2 diabetes in offspring.
In the Indian Mysore Parthenon cohort, higher maternal
25(OH)D status in pregnancy was associated with lower HDL-C
in males at 9.5 years (but not females).8 In our study, higher
maternal 25(OH)D in pregnancy was only associated with cardi-
oprotective levels of Apo-B, and not Apo-A1 or lipoproteins.
Neither of the previous studies had examined associations of
maternal 25(OH)D with offspring inﬂammatory markers, and
to our knowledge this is the ﬁrst study to report inverse associa-
tions of maternal 25(OH)D in pregnancy with CRP values in
Figure 2 Relative percentage differences (and 95% CI) in offspring outcomes at mean age 9.9 and 15.4 years, per 50 nmol/L of maternal
25-hydroxyvitamin D (25(OH)D) in pregnancy (N=4109). Associations are adjusted for maternal age at delivery, education level, pre-pregnancy body
mass index (BMI), smoking and physical activity during pregnancy, parity, socioeconomic position, ethnicity, and offspring gestational age at
maternal 25(OH)D sampling, gender, age and BMI at year 9.9 or 15.4 assessment. CRP, C reactive protein; DBP, diastolic blood pressure; HDL, high
density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure; Trigs, triglycerides.
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offspring. Although standard errors for associations were large
(and some conﬁdence intervals included the null), the point esti-
mates for these associations were strong, with CRP values in
adolescence decreasing by approximately 5.6% per 50 nmol/L
of 25(OH)D in pregnancy.
If such associations are causal and not a result of residual con-
founding, it is unclear how fetal exposure to 25(OH) D may
affect chronic inﬂammation (via supply of the active molecule
1,25(OH)2D). The vitamin D system may help to increase
the expression of T helper type 2 (Th2) cells and inhibit
T helper type 1 (Th1) cell differentiation during pregnancy.26
Over-expression of Th1 relative to Th2 (along with changes to
circulating cytokines produced by these cells) is thought to
increase the risk of conditions associated with adverse immuno-
modulation, such as pre-eclampsia.27 It is possible that the
determination of the T cell balance in pregnancy may also pro-
gramme long term immune responses in offspring. In line with
this hypothesis, higher maternal vitamin D intake or neonatal
25(OH)D status has been associated with reduced risk of child-
hood wheezing (which may depend on improved inﬂammatory
response) in offspring.7 28 However, further studies are neces-
sary to increase our understanding of mechanisms linking in
utero 25(OH)D exposure to lifelong inﬂammatory response.
Strengths and limitations
Our study has important strengths. It is several times larger than
the two existing studies of a similar nature, so we have greater
power to detect small but real associations. It is the ﬁrst to have
compared associations of maternal 25(OH)D with offspring car-
diovascular risk factors measured at time points in both child-
hood and adolescence. We were also able to examine whether
associations were due to shared familial characteristics that may
inﬂuence 25(OH)D concentrations of both mothers and off-
spring, rather than being due to intrauterine effects of maternal
25(OH)D alone. Finally, our analyses were conducted on a
large, non-select general population.
The main limitation of the study is attrition to participation
across the course of the study, which is common in longitudinal
cohorts. However, although there was statistical evidence for
differences in several characteristics between the eligible sample
and those excluded because of missing data on maternal
25(OH)D and/or offspring cardiovascular risk factors, these dif-
ferences were small in magnitude. Furthermore, attrition would
only introduce bias if the relationship between maternal
25(OH)D in pregnancy and offspring cardiovascular risk factors
was different in those who originally enrolled but had been sub-
sequently excluded, compared to our included sample, which
we do not anticipate. Maternal 25(OH)D was assessed using
single measures, so regression dilution may have occurred, and
reported results could be weaker than true associations.
However, 25(OH)D concentrations have been shown to correl-
ate strongly over time, so a single measure of 25(OH)D may
serve as an acceptable proxy for overall vitamin D status during
the period of exposure measurement (and similarly for child-
hood vitamin D status).29 30
CONCLUSIONS
The concept of increasing maternal 25(OH)D concentration
during pregnancy in order to improve non-skeletal health out-
comes in offspring is novel, and calls from health practitioners
advocating vitamin D supplementation in pregnancy for this
purpose may be premature. Although our results suggest the
possibility of associations of higher 25(OH)D with healthier
concentrations of CRP (and also Apo-B), further prospective
studies are required to conﬁrm the ﬁndings and experimental
studies are required to increase our understanding of potential
mechanisms. If ﬁndings are replicated elsewhere, randomised
controlled trials aimed at increasing maternal 25(OH)D concen-
trations in pregnancy would be warranted to see if vitamin D
supplementation can improve levels of chronic inﬂammation in
offspring.
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